EMA Authorised: Reyataz (atazanavir (as sulfate)) — Bristol-Myers Squibb Pharma EEIG

View source ↗

Summary

The EMA authorised Reyataz (atazanavir sulfate) for HIV infections; the marketing authorization holder is Bristol-Myers Squibb Pharma EEIG.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• REYATAZ (atazanavir)

Snippet

Status: Authorised. Therapeutic area: HIV Infections. MAH: Bristol-Myers Squibb Pharma EEIG. Decision date: 05/09/2024